The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The initiative will focus on advocating for cleaner air
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Subscribe To Our Newsletter & Stay Updated
